Catalyst Wire Dossier Catalyst Wire Dossier

HX008 + irinotecan

· Taizhou Hanzhong biomedical co. LTD
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HX008 + irinotecan, covering 2021-01-28 to 2021-01-28. Get the full timeline:

Most recent: Clinical Trial Update: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer [Phase 3]

See pricing